Navigation Links
Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Date:2/20/2008

nder applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
4. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
5. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
6. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Corporation (Nasdaq: RGEN ) today announced that ... to support the ongoing development of new treatments ... (MDA). This grant will support the completion ... of a drug candidate for human clinical trials. ... important funding for Repligen,s research but it also ...
(Date:12/15/2009)... and CHARLOTTESVILLE, Va., Dec. 15 ... the University of Virginia (UVa) in Charlottesville, ... a strategic research collaboration to enhance development ... disease (CAD) with a secondary focus on ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The collaborative preclinical ...
(Date:12/15/2009)... The Center for Business Intelligence (CBI), a ... announce the full agenda for the ... . The forum will take place at ... ,, Over 1,500 senior-level Finance, Accounting, Audit ... event since its inception, and this year,s ...
(Date:12/15/2009)... Law Office has announced the launch of several innovative ... legal services in the current economic climate. The ... opportunity to finance legal services over a period of ... equity in their start-up companies. The second is ... montly payment arrangements over 6 to 12 month period ...
Breaking Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2
... Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) announced today that ... has granted CTI,s request to transfer,the listing of its ... NASDAQ,Capital Market, which will be effective with the open ... continue to trade under the ticker symbol,CTIC. , ...
... Inc. (Nasdaq: MEDX ) announced today that it ... Healthcare Conference at 8:30 a.m. Pacific Time (11:30 a.m. Eastern ... webcast live and will be available in the Investor Relations ... archived edition of the presentation will be available following the ...
... that The Michael J. Fox Foundation has awarded it ... collaboration with The Parkinson,s Institute to evaluate Omeros, recent ... Parkinson,s disease. Located in regions of the brain responsible ... its novel target to the treatment of any movement ...
Other Biology Technology:Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market 2Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market 3Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 2Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 3
(Date:12/16/2009)... Maryland School of Medicine researcher will lead the coordinating ... scientists in the field of stem cell research. Michael ... was chosen by the National Heart, Lung and Blood ... of national experts, which will be called the NHLBI ... funded by a $30 million grant over seven years. ...
(Date:12/16/2009)... Dec. 1 GestureTek Inc. today ... 3.0 - a turnkey, portable, plug and ... exhibits, entertainment and touring promotions. GestureTek is ... patents in camera-enabled gesture recognition technology for ... Guaranteed for quality, the CUBE has TUV, ...
(Date:12/16/2009)... REDWOOD SHORES, Calif. and PALM HARBOR, Fla., ... ("CIC") (OTC Bulletin Board: CICI), a leading ... process automation in the financial industry* and ... and Docubase Systems Inc. ("Docubase"), a leading ... announced today that they have entered an ...
Breaking Biology News(10 mins):University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4Announcing ISMPP EU 2010 the First European Meeting of the International Society for Medical Publication Professionals Royal College of Physicians 15171 1Announcing ISMPP EU 2010 the First European Meeting of the International Society for Medical Publication Professionals Royal College of Physicians 15171 2Safe Life Ramps Production Capacity of Comfortable Breathable N95 Respirator Amid Worldwide Shortage 6997 1Safe Life Ramps Production Capacity of Comfortable Breathable N95 Respirator Amid Worldwide Shortage 6997 2Safe Life Ramps Production Capacity of Comfortable Breathable N95 Respirator Amid Worldwide Shortage 6997 3Safe Life Ramps Production Capacity of Comfortable Breathable N95 Respirator Amid Worldwide Shortage 6997 4European Radiotherapy Pioneers Deliver First Varian RapidArc 28TM 29 Treatment for Rectal Carcinoma Patient 6995 1European Radiotherapy Pioneers Deliver First Varian RapidArc 28TM 29 Treatment for Rectal Carcinoma Patient 6995 2European Radiotherapy Pioneers Deliver First Varian RapidArc 28TM 29 Treatment for Rectal Carcinoma Patient 6995 3
... risk of cardiovascular events -- a combined endpoint including ... -- in both men and women, according to a ... Duke University Medical Center cardiologist. , However, the researchers ... between the sexes. For men, aspirin lowered the risk ...
... that transplanted stem cells can regenerate damaged heart muscle in ... an intravenous infusion of adult mesenchymal stem cells from healthy ... tissue. , A unique benefit of the stem cell product ... IV line. Other therapies require delivery to the site ...
... are developing a method to determine in a matter of ... just by looking at the pattern of active genes in ... today at the ASM Biodefense Research Meeting. , "Effective prophylaxis ... rely upon early diagnosis and rapid initiation of therapy. ...
Other Biology News:Aspirin reduces cardiovascular risks in men and women -- but differently 2Aspirin reduces cardiovascular risks in men and women -- but differently 3Stem cell study for patients with heart attack damage seeks to regenerate heart muscle 2Stem cell study for patients with heart attack damage seeks to regenerate heart muscle 3Gene patterns in white blood cells quickly diagnose disease 2
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
... is a genetically engineered Klenow polymerase in which ... removed, leaving only the 5 to 3 polymerase ... Klenow Fragment the enzyme of choice for isotopic ... random primed method, and for DNA sequencing by ...
Request Info...
Biology Products: